Nutriband Inc. (NASDAQ: NTRB, NASDAQ: NTRBW) announced it has received a Notice of Publication from the United States Patent and Trademark Office (USPTO), dated September 2, 2026, for commercial brand name trademarks related to its abuse-deterrent fentanyl transdermal system.

The trademarks will be published in the USPTO Trademark Official Gazette. If no objections are filed within the 30-day opposition period, the USPTO is expected to issue a Notice of Allowance. Once allowed, Nutriband plans to submit the commercial brand name to the FDA and other international regulatory agencies for review and approval.

The product is based on the company's AVERSA™ transdermal technology, which incorporates aversive agents into patches to deter abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. Patents for the technology have been issued in 46 countries, including the United States, Europe, Japan, China, and Canada.

Nutriband is an Orlando, Florida-based company focused on the development of prescription transdermal pharmaceutical products. The information in this article is based on a company press release.